Researchers find better way to save sight

March 15, 2012

People who are losing their eyesight through aged-related macular degeneration (AMD) may soon be able to find out if a commonly used drug can help save their vision.

Researchers at The Vision Centre and The Australian National University have found a new way to measure the effectiveness of the drug ranibizumab for patients suffering the ‘wet’ form of AMD and help doctors decide on the best treatment for new patients. accounts for half of the vision loss cases in Australia, costing the nation $2.6 billion a year. People with Wet AMD suffer from an outgrowth of new blood vessels at the back of their eyes which invade their retinas, leading to progressive blindness. Ranibizumab is a standard treatment that shrinks the blood vessels and helps prevents any further growth.

“A common test to see if the drug works involves getting the patient to look at an eye chart,” says Professor Ted Maddess, the director of The Vision Centre and one of the researchers in the study. “These responses can be subjective and less accurate partly because we’re asking the patients to use their own judgement as to whether they can see better.

“A more objective method involves attaching wires to the patients’ scalp and testing their vision through the electrical responses of their brain. The downside to this test is that it takes too long to set up and doctors or optometrists usually do not have the staff or the equipment to perform it.

“Our new test uses a video camera with infrared lights to watch how the pupils respond to images on an LCD screen. The little movements of the pupils help us make a map of how well each part of their retina is functioning. This provides us with a reliable objective test that does not involve contacting the eye or brain.”

Using a device known as the Truefield Analyzer, developed by Prof. Maddess’ team, the researchers uses displays to provide multiple stimuli to each eye, at 44 locations in the patients’ visual field. The video of the patients’ eyes is processed by a computer to establish a record of the instantaneous response of their pupils.

By watching pupil responses – and so measuring the retinal function – of patients before and after treatment, the test can quantify the amount of improvement as a result of the drug.

“It wasn’t just a yes or no answer to whether the drug was working or not – we can actually track the progress of the improvement,” Prof Maddess says.

The surprising finding was that the test can often be used to predict if a new patient willrespond well to the drug.

“An indication of good pupil response is the speed and the size of its contraction – healthy eyes have bigger responses or react quicker. We found that new who had good responses before their first treatment generally reacted better to the drug, and vice versa.

“Testing for responses is important because is a very expensive drug, and is administered by injection into the patient’s eye. With the new test, doctors can better assess how the patient will respond, and decide whether this drug is best for them.

“This holds a promising role of predicting if a treatment will work for a patient. So we hope that will assist development as well.”

The group’s paper “Multifocal pupillography identifies Ranibizumab-induced changes in retinal function for exudative age-related macular degeneration” by Faran Sabeti, Ted Maddess, Rohan W. Essex and Andrew C. James has been published in the latest issue of Investigative Ophthalmology & Visual Science.

Explore further: Scientists keep their eyes on peripheral vision

Related Stories

Scientists keep their eyes on peripheral vision

January 20, 2012
(Medical Xpress) -- Two USC scientists are bringing peripheral vision into focus, showing that the way the brain sharpens its attention while the eyes are in motion leads to false assumptions about how objects should look.

Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration

June 13, 2011
A computer modeling study suggests that administering the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration in non-Hispanic white ...

Recommended for you

Genome editing with CRISPR-Cas9 prevents angiogenesis of the retina

July 24, 2017
A research team from the Schepens Eye Research Institute of Massachusetts Eye and Ear has successfully prevented mice from developing angiogenesis of the retina—the sensory tissue at the back of the eye—using gene-editing ...

Too little vitamin D may hinder recovery of injured corneas

July 24, 2017
Injury or disease in combination with too little vitamin D can be bad for the window to your eyes.

Combination of type 2 diabetes and sleep apnoea indicates eyesight loss within four years

July 4, 2017
Research led by the University of Birmingham has discovered that patients who suffer from both Type 2 diabetes and obstructive sleep apnoea are at greater risk of developing a condition that leads to blindness within an average ...

Nearly 60% of pinkeye patients receive antibiotic eye drops, but they're seldom necessary

June 28, 2017
A new study suggests that most people with acute conjunctivitis, or pinkeye, are getting the wrong treatment.

Magnetic implants used to treat 'dancing eyes'

June 26, 2017
A research team has successfully used magnets implanted behind a person's eyes to treat nystagmus, a condition characterised by involuntary eye movements.

Drug shows promise against vision-robbing disease in seniors

June 21, 2017
An experimental drug is showing promise against an untreatable eye disease that blinds older adults—and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.